Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma
1. Higher rates of treatment response were observed in patients receiving isatuximab with carfilzomib–dexamethasone than carfilzomib–dexamethasone alone. 2. Improved median ...